Drug Approval | June 01, 2026
Wockhardt wins FDA nod for new antibiotic ZAYNICH against drug-resistant infections
The approval marks a major milestone in the global fight against antimicrobial resistance
The approval marks a major milestone in the global fight against antimicrobial resistance
The results confirm the study’s primary endpoint of objective response rate and now deliver a striking signal in progression-free survival
This marks one of the most closely watched oncology readouts at this year’s medical congress
Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
Subscribe To Our Newsletter & Stay Updated
